Differential gene expression in progesterone-sensitive and progesterone-insensitive endometrial carcinoma cells

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 82, Issue 2, 1999, Pages 135-138

  Koopman, E ^a   Blok, L J ^b   Brinkmann, A O ^b   Helmerhorst, Th J M ^a   Huikeshoven, F J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Differential display PCR; Endometrial carcinoma; Genes; Progesterone therapy

Indexed keywords

COMPLEMENTARY DNA; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0033009164     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00214-0     Document Type: Conference Paper

References (11)

1. Schottenfeld D. Epidemiology of endometrial neoplasia. J Cell Biochem. 23:1995;151-159.
2. Maneschi M., Maneschi F., Geraci P.et al. Surgical pathological staging of endometrial carcinoma and results of treatment. Eur J Gynaecol Oncol. 13(1):1992;30-35.
3. Lentz S.S. Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin Oncol. 21(1):1994;100-106.
4. Lindahl B., Willen R. Endometrial hyperplasia. Anticancer Res. 11(1):1991;403-406.
5. Fearon E.R., Vogelstein B.A. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
6. Knudsen A.G. All in the (cancer) family. Nat Genet. 5:1993;103-104.
7. Chang G.T.G., Blok L.J., Steenbeek M., Veldscholte J., van Weerden W.M., van Steenbrugge G.J., Brinkmann A.O. Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res. 57:1997;4075-4081.
8. Auffray C., Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem. 107(2):1980;303-314.
9. Esteller M., Garcia A., Martinez-Palones J.M., Xercavins J., Reventos J. The clinicopathological significance of K-ras point mutation and gene amplification in endometrial cancer. Eur J Cancer. 33(10):1997;1572-1577.
10. Jones M.W., Kounelis S., Hsu C., Papadaki H., Bakker A., Swalsky P.A., Finkelstein S.D. Prognosic value of P53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicalpathologic and molecular comparison. Int J Gynecol Pathol. 16(4):1997;354-360.
11. Berchuck A., Boyd J. Molecular basis of endometrial cancer. Cancer. 76:1995;2034-2040.